July 2nd 2024
Kisunla (donanemab-azbt) is now approved by the FDA for adults with early symptomatic Alzheimer disease.
Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease
Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.
Read More